# Title
LUMEN COMPANY INSIGHT: QUIDELORTHO Q1 FY2025 RESULTS REVIEW

# Summary
1. Event Recognition

QuidelOrtho (NASDAQ: QDEL) reported its Q1 FY2025 results:
   • Revenue: $692.8 million, slightly above analysts' expectations of $689.8 million, though down 2.6% year-over-year.
   • Adjusted EPS: $0.74, exceeding the expected $0.59 by 25%.
   • Adjusted EBITDA: $159.8 million, surpassing the expected $149.4 million by 7%, with a margin of 23.1%.
   • Full-year revenue guidance: The company reaffirmed its annual revenue expectation of $2.71 billion, aligning with market expectations.
   • Full-year EPS guidance: Expected adjusted EPS of $2.32, consistent with market expectations.
   • Full-year EBITDA guidance: Estimated annual EBITDA of $595 million, in line with expectations.
   • Operating margin: 4.7%, a significant improvement from -247% in the prior year.
   • Constant currency revenue: Down 1.1%, compared to -15.5% last year.
   • Market capitalization: $1.75 billion.

⸻

# News Comment
1. Event Recognition

QuidelOrtho (NASDAQ: QDEL) reported its Q1 FY2025 results:
   • Revenue: $692.8 million, slightly above analysts' expectations of $689.8 million, though down 2.6% year-over-year.
   • Adjusted EPS: $0.74, exceeding the expected $0.59 by 25%.
   • Adjusted EBITDA: $159.8 million, surpassing the expected $149.4 million by 7%, with a margin of 23.1%.
   • Full-year revenue guidance: The company reaffirmed its annual revenue expectation of $2.71 billion, aligning with market expectations.
   • Full-year EPS guidance: Expected adjusted EPS of $2.32, consistent with market expectations.
   • Full-year EBITDA guidance: Estimated annual EBITDA of $595 million, in line with expectations.
   • Operating margin: 4.7%, a significant improvement from -247% in the prior year.
   • Constant currency revenue: Down 1.1%, compared to -15.5% last year.
   • Market capitalization: $1.75 billion.

⸻

2. Motivation Analysis

QuidelOrtho's revenue performance this quarter met market expectations despite a slight year-over-year decline of 2.6%, with adjusted EPS and EBITDA exceeding expectations, highlighting growth advantages in cost control and market share. Notably, the operating margin rebounded from -247% to 4.7%, indicating significant improvements in operational efficiency and cost management. Additionally, the full-year revenue, EPS, and EBITDA guidance were not lowered, reflecting management's confidence in future growth.

⸻

3. Structural Insight

QuidelOrtho's core business focuses on medical diagnostics and in vitro diagnostics (IVD) products, covering laboratory testing and at-home rapid tests. The report indicates that while revenue declined slightly, the profit structure improved significantly with the operating margin turning positive at 4.7%, showcasing effective internal cost control. Furthermore, the constant currency revenue only decreased by 1.1%, a substantial improvement from the previous year’s 15.5%, indicating that currency impacts on international business are being absorbed. The overall financial structure appears more robust, particularly in adjusted EBITDA, which surpassed market expectations by 7%.

⸻

4. Key Variables
   • Growth in the laboratory testing market: As a core revenue source, sustained demand for laboratory testing is critical for future revenue.
   • Operational efficiency and cost control: Continued improvement in profit margins will drive long-term growth.
   • Currency impact in international markets: Stabilizing constant currency revenue is key for future performance.
   • Technology and product updates: Rapid technological changes in the IVD market will determine QuidelOrtho's market share.

⸻

5. Trend Forecast

If QuidelOrtho can continue optimizing cost management and expand the market for laboratory testing and rapid test products, its EBITDA and operating margin are likely to grow. Additionally, mitigating currency risks in international markets will aid in revenue recovery. Stable demand in the medical diagnostics market and the introduction of new products will be major growth drivers going forward.

⸻

LUMEN Structural Analysis

QuidelOrtho's financial report reflects improvements in structural growth; despite a slight revenue decline, cost control and margin recovery indicate enhanced internal management efficiency. From LUMEN's perspective, the core structural optimization of QuidelOrtho is evident in the robust growth of the laboratory testing business and improved operational efficiency. Structural analysis indicates the company is recovering from previously high operational costs, with market share and profit margins expanding. Continued enhancement of international market stability and product technology updates will lead to a more rational and sustainable growth path.
